I N N O V A T I O N

Product Pipeline

The ELIAS Cancer Immunotherapy (ECI®) is the first ever approved product for the treatment of canine osteosarcoma. ECI® has been evaluated in multiple clinical studies and has been used to treat cancer in more than 300 canine patients, both in clinical studies and commercially.

ECI® is a vaccine-enhanced adoptive cell therapy that trains the immune system to target a patient’s unique cancer cells. This personalized approach can improve clinical outcomes and provide a better quality of life for canine patients. As a USDA-approved Autologous Prescription Product, ECI® can also be used by licensed veterinarians to treat other cancers.

ELIAS Animal Health is developing an oncolytic virotherapy to treat a variety of tumoral cancers in companion animals. ELI352 is a vaccinia viral strain that selectively replicates in cancer cells, causing cell death (apoptosis).¹ Though oncolytic viruses only target cancer cells and not healthy cells, they are not selective about which cancer types they attack, making them potentially useful against a variety of cancer types. ELIAS plans to evaluate ELI352 in various indications, including osteosarcoma, oral melanoma, lymphoma, and mast cell tumors.

ELIAS licensed the technology from Genelux Corporation, a clinical stage immuno-oncology company focused on advancing treatments for a broad range of cancer indications in humans. Genelux previously conducted a Phase 1 study in which this oncolytic virus was used to treat dogs diagnosed with several types of cancer.